Master One Thing - Rapamycin Longevity Series cover image

Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging

Master One Thing - Rapamycin Longevity Series

00:00

Joining Novartis to Study Aging

Joan explains being recruited to Novartis' New Indications unit and gaining support to study mTOR and aging.

Play episode from 03:40
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app